CFTR and cystic fibrosis: The need for CF sequencing is also highlighted by Amaral and Harrison (2023), who reported that although CFTR modulator therapies are now available, there is a need for further drug development to tackle the basis of CF cellular defects to improve clinical benefits for affected individuals and those with CFTR-related disorders.